OTC:BZYR
BURZYNSKI RESEARCH INSTITUTE INC
A high-risk biotech developer of proprietary amino acid molecule cancer therapies with zero current revenue but substantial historical financial backing.
Key Metrics
Investment Thesis
Bull Case
An investor might consider this stock for speculative purposes if they believe the proprietary AAMT technology is underappreciated and that the recent financing activity indicates renewed strategic interest from major stakeholders or partners. The deep loss position could potentially reset expectations, allowing any future FDA approval to result in an immediate, massive multiple expansion if the company successfully transitions to revenue generation.
Bear Case
The stock should be avoided by rational investors due to a catastrophic balance sheet where current assets are negligible compared to liabilities and a retained earnings deficit exceeding $129M. With zero revenue, negative net income of -$1.4M, and no cash flow from operations, the company has no path to organic survival and faces an imminent risk of insolvency or total capitalization loss.
About BURZYNSKI RESEARCH INSTITUTE INC
Burzynski Research Institute Inc (BZYR) is a specialized biotechnology firm focused on developing cancer treatments using the proprietary Amino Acid Molecule Therapy (AAMT). The company operates primarily in the United States, leveraging its decades-long research history to pursue FDA approval for its flagship drug, AP101. While currently showing no revenue, the business model relies heavily on high-risk clinical development with significant historical cash burn.
Analysis
Management Discussion
Despite generating zero revenue, the company incurred a net loss of $1.4M in the latest fiscal year, driven entirely by general and administrative expenses of $340k and R&D costs of $1.0M without offsetting income. The cash flow from operations was negative at -$388,531 while cash flow from financing provided a one-time injection of $388,068, highlighting the company's total dependence on external capital injections to survive rather than operational profitability.
Industry Overview
The biotechnology industry is characterized by high failure rates where companies spend billions on R&D before achieving commercial success, but this specific sub-sector of amino acid therapy remains highly niche and controversial within the oncology landscape. Investors in this space typically accept years of negative earnings and cash burn as a cost of validating proprietary science before any potential market entry.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $916.3K | $1.3M | $1.4M |
| Operating Income | $-916.3K | $-1.3M | $-1.4M |
| R&D | $718.5K | $865.0K | $1.0M |
| G&A | $197.8K | $470.4K | $340.3K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Pre-Tax Income | $-916.3K | $-1.3M | $-1.4M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-916.3K | $-1.3M | $-1.4M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-916.3K | $-1.3M | $-1.4M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-916.3K | $-1.3M | $-1.4M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $1.9K | $2.3K | $847 |
| Cash & Equivalents | $934 | $1.3K | $847 |
| Other Current Assets | $1.0K | $1.0K | $0 |
| Long-Term Assets | $0 | $0 | $0 |
| Total Assets | $1.9K | $2.3K | $847 |
| Accounts Payable | $12.6K | $9.0K | $17.0K |
| Total Liabilities | $15.7K | $27.4K | $42.5K |
| Shareholders' Equity | $-13.7K | $-25.1K | $-41.6K |
| Retained Earnings | $-126.8M | $-128.1M | $-129.5M |
| Total L&E | $1.9K | $2.3K | $847 |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-916.3K | $-1.3M | $-1.4M |
| Non-Cash Adjustments | $654.8K | $799.9K | $983.6K |
| Working Capital Changes | $11.9K | $11.8K | $14.1K |
| Cash from Operations | $-249.5K | $-523.8K | $-388.5K |
| Cash from Investing | $0 | $0 | $0 |
| Cash from Financing | $247.1K | $524.2K | $388.1K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-2.4K | $376 | $-463 |
| Beginning Cash | $3.4K | $934 | $1.3K |
| Ending Cash | $934 | $1.3K | $847 |
Frequently Asked Questions
How does BURZYNSKI RESEARCH INSTITUTE INC make money?
The company operates through a single primary segment focused on research and development of its proprietary Amino Acid Molecule Therapy for solid tumors, currently generating no product revenue as it remains in the clinical trial or pre-commercialization phase.
What are the main risks for BZYR?
1. Severe liquidity crisis with zero revenue, negative net income of -$1.4M in 2025, and cash flow from operations at -$388k indicating an inability to fund operations organically. 2. Extreme balance sheet fragility with total liabilities of $42,484 exceeding current assets of only $847 and a massive retained earnings deficit of -$129.5M. 3. High risk of delisting or forced liquidation due to OTC status combined with inability to raise capital given the deep burn rate and lack of product sales.
What is BZYR's competitive advantage?
1. Proprietary AAMT technology with over 25 years of historical research data supporting efficacy claims. 2. Strong historical financial backing evidenced by a $129.4M non-controlling interest balance sheet suggesting significant external support or capital structure complexity. 3. Specialized regulatory strategy targeting FDA approval for AP101 based on established pre-clinical and early clinical evidence.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.